Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma

BACKGROUND: Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. However, the therapeutic effect of solid tumors is limited. One of the most important factors is the homing of CAR-T cells to tumor tissues...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Min, Wu, Yi-chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437660/
https://www.ncbi.nlm.nih.gov/pubmed/34527749
http://dx.doi.org/10.1155/2021/1782728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437660/
https://www.ncbi.nlm.nih.gov/pubmed/34527749
http://dx.doi.org/10.1155/2021/1782728

Ejemplares similares